Provided by Tiger Fintech (Singapore) Pte. Ltd.

Capricor Therapeutics

14.23
+1.057.97%
Pre-market: 14.660.4300+3.02%08:50 EDT
Volume:2.51M
Turnover:35.06M
Market Cap:650.42M
PE:-10.02
High:14.35
Open:13.26
Low:12.80
Close:13.18
Loading ...

Capricor Therapeutics Announces FDA Acceptance and Priority Review of Its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy

THOMSON REUTERS
·
04 Mar

Capricor Therapeutics Inc - FDA Assigns Pdufa Target Action Date of August 31, 2025

THOMSON REUTERS
·
04 Mar

Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy

GlobeNewswire
·
04 Mar

Capricor Therapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview

Reuters
·
04 Mar

Capricor Therapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview

Reuters
·
28 Feb

Capricor Therapeutics options imply 31.0% move in share price post-earnings

TIPRANKS
·
28 Feb

Capricor Therapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview

Reuters
·
24 Feb

High Growth Tech Stocks In The United States To Watch

Simply Wall St.
·
18 Feb

Strength Seen in Exagen (XGN): Can Its 29.4% Jump Turn into More Strength?

Zacks
·
05 Feb

Capricor Therapeutics (NASDAQ:CAPR) delivers shareholders fantastic 54% CAGR over 5 years, surging 12% in the last week alone

Simply Wall St.
·
22 Jan

Capricor Therapeutics: Promising Advances in Duchenne Cardiomyopathy Treatment Drive Buy Rating

TIPRANKS
·
04 Jan

CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA

Zacks
·
03 Jan

Capricor Therapeutics Price Target Maintained With a $77.00/Share by HC Wainwright & Co.

Dow Jones
·
03 Jan

Capricor Therapeutics: Strategic Advances and Regulatory Progress Drive Buy Rating

TIPRANKS
·
02 Jan

Capricor Completes BLA Submission for Deramiocel to Treat DMD Cardiomyopathy

MT Newswires Live
·
02 Jan

Capricor Therapeutics completes submission of BLA to FDA for deramiocel

TIPRANKS
·
02 Jan

Capricor Therapeutics Completes Submission Of Biologics License Application To The U.S. FDA For Deramiocel

T-Reuters
·
02 Jan

Capricor Therapeutics - Bla Submission Triggers $10 Mln Milestone Payment to Capricor From Nippon Shinyaku

THOMSON REUTERS
·
02 Jan

Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

THOMSON REUTERS
·
02 Jan

RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead

Dow Jones
·
13 Dec 2024